Literature DB >> 1378146

Carvedilol in hypertension: effects on hemodynamics and 24-hour blood pressure.

P Lund-Johansen1, P Omvik, J E Nordrehaug, W White.   

Abstract

Nineteen men (mean age, 44 years) with moderately severe essential hypertension were studied invasively at rest and during exercise. After initial predrug recordings, patients received 25 mg carvedilol orally, and central hemodynamics at rest and during exercise were recorded 1 and 2 h after tablet intake to evaluate the immediate effects of carvedilol. Blood pressure decreased by 11% within 1 h, and the hemodynamic results indicated a combination beta-blocking and vasodilating effect. After 6-9 months of treatment (dose, 25-100 mg), supine hemodynamics were recorded, first 12-24 h after the last dose and then 1 and 2 h after an additional 25-mg dose. During chronic treatment (2 h after the last dose with the patient at rest and in the supine position), mean arterial pressure was reduced by 17% (p less than 0.001) and total peripheral resistance index was reduced by 6% (NS), whereas heart rate and cardiac index were reduced by 12%. Exercise hemodynamics demonstrated a decrease in blood pressure of 17% (p less than 0.001). Exercise stroke index increased by 5% (NS), in part compensating for the reduction in heart rate of 17%. Total peripheral resistance index was reduced by 5% (NS). Twenty-four-hour blood pressure monitoring (Accutracker II) demonstrated significant blood pressure reductions in awake as well as in asleep patients. Blood pressures decreased from 163/102 to 141/84 mm Hg in from 135/78 to 122/68 mm Hg in awake and asleep patients; respectively. Carvedilol is an effective antihypertensive agent, and the hemodynamic mode of action reflects alpha 1- and beta 1-blocking activities.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1378146

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  6 in total

Review 1.  An overview of the pharmacodynamic properties and therapeutic potential of combined alpha- and beta-adrenoceptor antagonists.

Authors:  P A van Zwieten
Journal:  Drugs       Date:  1993-04       Impact factor: 9.546

Review 2.  Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  D McTavish; D Campoli-Richards; E M Sorkin
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

3.  Comparison of the hemodynamic effects of metoprolol and carvedilol in hypertensive patients.

Authors:  K Weber; T Bohmeke; R van der Does; S H Taylor
Journal:  Cardiovasc Drugs Ther       Date:  1996-05       Impact factor: 3.727

4.  Long-term hemodynamic effects at rest and during exercise of newer antihypertensive agents and salt restriction in essential hypertension: review of epanolol, doxazosin, amlodipine, felodipine, diltiazem, lisinopril, dilevalol, carvedilol, and ketanserin.

Authors:  P Omvik; P Lund-Johansen
Journal:  Cardiovasc Drugs Ther       Date:  1993-04       Impact factor: 3.727

5.  Carvedilol increases blood pressure response to phenylephrine infusion in heart failure subjects with systolic dysfunction: evidence of improved vascular alpha1-adrenoreceptor signal transduction.

Authors:  Benjamin W Van Tassell; Matthew T Rondina; Franklin Huggins; Edward M Gilbert; Mark A Munger
Journal:  Am Heart J       Date:  2008-06-20       Impact factor: 4.749

Review 6.  Use of carvedilol in hypertension: an update.

Authors:  Gastone Leonetti; Colin G Egan
Journal:  Vasc Health Risk Manag       Date:  2012-05-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.